Stocks and Investing
Stocks and Investing
Mon, April 2, 2018
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Thu, March 29, 2018
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Arlinda Lee Maintained (AKTX) at Strong Buy with Decreased Target to $160 on, Mar 29th, 2018
Arlinda Lee of Canaccord Genuity, Maintained "Akari Therapeutics, Plc" (AKTX) at Strong Buy with Decreased Target from $300 to $160 on, Mar 29th, 2018.
Arlinda has made no other calls on AKTX in the last 4 months.
There is 1 other peer that has a rating on AKTX. Out of the 1 peers that are also analyzing AKTX, all agrees with Arlinda's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Madhu Kumar of "B. Riley Securities" Initiated at Hold and Held Target at $60 on, Thursday, February 8th, 2018
Contributing Sources